Moderna has secured FDA approval for its respiratory syncytial virus (RSV ... and Pfizer’s products. There’s still one more step before Moderna’s vaccine can take on Arexvy and Abrysvo ...

The respiratory syncytial virus (RSV) vaccine produced strong immune responses in older adults during its first two seasons of use, according to a new study.

Pfizer is also running a phase 3 trial of Abrysvo in adults aged 18 to 59 at elevated risk of RSV disease due to chronic medical conditions, but data from that isn't due until later this year.

Please note that sales of Pfizer’s PFE RSV vaccine, Abrysvo, and GSK plc’s GSK RSV vaccine Arexvy also declined in the fourth quarter. This downtick can be attributed to the restrictive ...

The syndrome has cropped up as a side effect in trials for RSV vaccines like Pfizer’s Abrysvo and GSK’s Arexvy. The single case of Guillain-Barré syndrome in the mRNA-1403 trial is ...

Respiratory syncytial virus (RSV) is known to cause considerable respiratory infection-related morbidity and mortality worldwide.1,2 Estimates published in 2022 from the UK highlight the ...

PFE’s RSV vaccine Abrysvo is approved for older adults, as well as infants through maternal immunization. The vaccine is also approved for the prevention of lower respiratory tract disease (LRTD ...

With the safePICO self-fill blood gas syringe, you can improve your mixing and get results you can trust. Mixing ball helps you obtain a homogeneous sample SafeTIPCAP minimizes the risk of blood ...